Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

China's State Development and Investment Corporation has picked up an 18.6% stake in Sihuan Pharmaceutical’s drug development spinoff, Xuanzhu Biopharmaceutical.

Lilly Asia Ventures was among the new investors in a series C round for autoimmune and inflammatory disease drug developer Connect Biopharma.

TearClear has raised $34.8m to date to fund an anti-preservative eye drop technology invented at University of Florida.

Baxter Ventures is set to exit the kidney dialysis device maker, which has just filed to go public following upwards of $430m in venture funding.

The medical data software producer has filed to float in Hong Kong after raising nearly $340m from investors including Tencent and Sunshine Insurance.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The SK Telecom, iA Financial, Foxconn and Fujifilm-backed X-ray technology developer priced the offering at the top of its range.

The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.

GlaxoSmithKline’s Action Potential Venture Capital fund led a series B-plus round that included TDK Ventures, Intel Capital and Applied Ventures.